Senores Pharmaceuticals Limited has published the extracts of its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. These results were published in the Financial Express (English and Gujarati editions) on January 21, 2026. The company has also uploaded this information on its website, www.senorespharma.com, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The publication includes detailed financial figures for various periods, such as the quarter ended December 31, 2025, and the nine months ended December 31, 2025, alongside comparative figures for the previous year. The announcement also provides details on the company's revenue, profit after tax, and earnings per share for these periods. Notably, the company's revenue for the nine months ended December 31, 2025, stood at ₹986.09 crore, with a consolidated profit after tax of ₹455.83 crore for the same period. The company also provided its outlook for FY26, projecting a revenue of ₹12.5 crore and earnings per share of ₹3.3 for its biopharmaceutical business, with further details on its revenue targets and planned investments.
